Inhalation of a dry powder ciprofloxacin formulation in healthy subjects: a phase I study.

First published in Clinical Drug Investigation on 2013 Jun.
Clin Drug Investig. 2013 Jun;33(6):419-27. doi: 10.1007/s40261-013-0082-0

Authors: Stass H, Nagelschmitz J, Willmann S, Delesen H, Gupta A, Baumann S

Abstract

Background

Oral and intravenous formulations of ciprofloxacin have established efficacy and safety profiles in respiratory infections. A dry powder for inhalation (DPI) that uses Novartis‘ PulmoSphere™ technology has been developed to deliver high concentrations of ciprofloxacin to the lung with low systemic exposure using a portable and convenient passive dry powder inhaler (Novartis‘ T-326 inhaler).
 

Objectives

The primary objective was to investigate the safety and tolerability of ciprofloxacin DPI in healthy male subjects, with a secondary objective to investigate the pharmacokinetics of ciprofloxacin after ciprofloxacin DPI administration.
 

Results

Ciprofloxacin DPI was well tolerated with no clinically relevant adverse effects on lung function. Estimates of lung deposition derived from physiology-based pharmacokinetic modelling suggest that approximately 40 % of the total dose of ciprofloxacin DPI reached the trachea/bronchi and alveolar space. Systemic ciprofloxacin was detected soon after inhalation [peak concentration in plasma (C(max)) 56.42 μg/L, median time to C max 0.625 h], but total systemic exposure was minimal (area under the plasma concentration-time curve 354.4 μg·h/L). Terminal elimination half-life (9.5 h), apparent total clearance from plasma after non-intravenous administration (91.7 L/h) and apparent volume of distribution (1,262 L) data suggest that elimination from the respiratory tract was prolonged.

Conclusions

In healthy subjects, ciprofloxacin DPI was well tolerated, delivered ciprofloxacin to the lungs and resulted in minimal systemic exposure, allowing further investigation of its clinical use for the management of specific, chronic infections in pulmonary diseases.
 

Read more

Download full article as Pdf file:

Pdf File 1

Pdf File 2

 

REACHING OUT IS EASY AND FAST – LET’S TALK

Dr. Marc Hetzel

VP & Head of Business Development
located at CRS Management


LET’S TALK BUSINESS